ONL | Jotup

Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on:

Jeudi, mai 2, 2024

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Key Points:

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.
Kriya’s pipeline includes gene therapies across several therapeutic areas including ophthalmology, metabolic disease and neurology.
Broad coverage was achieved from the injection site to the posterior pole, including the macula and retina.
The study demonstrates, in a dose dependent manner, the potential of AAV.CR2-CR1 to preserve the photoreceptor-containing outer nuclear layer (ONL).

Orion Office REIT Inc. Announces First Quarter 2024 Earnings Release and Webcast Dates

Retrieved on:

Vendredi, avril 12, 2024

Commercial Building & Real Estate, Construction & Property, REIT, Webcast, Internet, Orion, ONL, Acquisition

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.

Key Points:

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.
The webcast and call will be hosted by Paul McDowell, Chief Executive Officer and President, and Gavin Brandon, Chief Financial Officer, Executive Vice President and Treasurer.
To participate, the webcast can be accessed live by visiting the “Investors” section of Orion’s website at onlreit.com/investors.
A replay of the webcast may be accessed via the Internet by visiting the “Investors” section of Orion’s website at onlreit.com/investors .

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

Retrieved on:

Mardi, janvier 23, 2024

ANN, Patient, Therapy, RRD, Clinical trial, University, ONL, Safety, Visual Science, Retina, Club, Pharmaceutical industry

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Zacks, M.D., Ph.D., chief scientific officer and co-founder of ONL Therapeutics, and the Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center of the University of Michigan, will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment (RRD) at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.

Key Points:

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Zacks, M.D., Ph.D., chief scientific officer and co-founder of ONL Therapeutics, and the Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences at the Kellogg Eye Center of the University of Michigan, will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment (RRD) at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.
“We believe our Phase 2 randomized study to assess the safety and efficacy of intravitreal ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD) could play an important role in treating this vision-threatening condition, and we look forward to sharing an update at the Macula Society meeting,” said David Esposito, chief executive officer of ONL Therapeutics.
“With the study now fully enrolled we will focus our attention on gathering and analyzing the data with a goal to share topline results in the second quarter of 2024.”
Details of the podium presentation are as follows:
Fas Inhibition with ONL1204 for Macula-off Rhegmatogenous Retinal Detachment (RRD): Study Population Data on a Phase 2, Multicenter, Randomized, Sham-controlled, Single-Masked, Clinical Trial
Edna H. Perkiss Research Professor of Ophthalmology and Visual Sciences, Kellogg Eye Center

Orion Office REIT Inc. Announces Tax Treatment of 2023 Dividends

Retrieved on:

Jeudi, janvier 25, 2024

Commercial Building & Real Estate, Construction & Property, REIT, Classification, Income tax, ONL, CUSIP, Acquisition

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today the income tax classification of its 2023 dividends for the Company’s common stock (“Common Stock”).

Key Points:

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today the income tax classification of its 2023 dividends for the Company’s common stock (“Common Stock”).
The table below summarizes the income tax classification of the dividends paid and the corresponding box number on the 2023 Form 1099-DIV.
Stockholders are encouraged to consult with their tax advisors as to their specific treatment of ONL dividends.
ONL Common Stock | CUSIP: 68629Y103

Orion Office REIT Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Webcast Dates

Retrieved on:

Mardi, janvier 23, 2024

Construction & Property, REIT, ONL, Acquisition, Orion, Internet, Webcast

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.

Key Points:

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.
The webcast and call will be hosted by Paul McDowell, Chief Executive Officer and President, and Gavin Brandon, Chief Financial Officer, Executive Vice President and Treasurer.
To participate, the webcast can be accessed live by visiting the “Investors” section of Orion’s website at onlreit.com/investors.
A replay of the webcast may be accessed via the Internet by visiting the “Investors” section of Orion’s website at onlreit.com/investors .

Orion Office REIT Inc. Announces Third Quarter 2023 Results

Retrieved on:

Jeudi, novembre 9, 2023

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today its operating results for the third quarter ended September 30, 2023.

Key Points:

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today its operating results for the third quarter ended September 30, 2023.
The Company’s net loss attributable to common stockholders was $(16.5) million, or $(0.29) per share, during the third quarter of 2023, as compared to $(53.0) million, or $(0.94) per share, reported in the same quarter of 2022.
Core FFO for the third quarter of 2023 was $24.1 million, or $0.43 per share, as compared to $25.6 million, or $0.45 per share in the same quarter of 2022.
The Company’s 2023 General and Administrative Expenses guidance range of $18.25 million to $18.75 million is unchanged from last quarter.

Orion Office REIT Inc. Announces Third Quarter 2023 Earnings Release and Webcast Dates

Retrieved on:

Mercredi, octobre 11, 2023

REIT, Finance, Professional Services, Commercial Building & Real Estate, Construction & Property, Internet, NYSE, Webcast, Acquisition, Orion, ONL, Cryptocurrency

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.

Key Points:

Orion will host a webcast and conference call to review its financial results at 10:00 a.m.
The webcast and call will be hosted by Paul McDowell, Chief Executive Officer and President, and Gavin Brandon, Chief Financial Officer, Executive Vice President and Treasurer.
To participate, the webcast can be accessed live by visiting the “Investors” section of Orion’s website at onlreit.com/investors.
A replay of the webcast may be accessed via the Internet by visiting the “Investors” section of Orion’s website at onlreit.com/investors .

ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

Retrieved on:

Lundi, août 28, 2023

Retina, Partnership, RRD, ANN, Geographic atrophy, IVT, ONL, Patient, Therapy, Safety, Pharmaceutical industry

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD). The ongoing Phase 2 clinical trial is a randomized, controlled study designed to assess 135 patients across three arms, including two treatment groups and a sham group. The goal of the study is to evaluate the safety and efficacy of a single intravitreal (IVT) injection of ONL1204 as an adjunct to standard-of-care surgical repair in subjects with macula-off RRD at 37 sites across the United States.

Key Points:

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).
The ongoing Phase 2 clinical trial is a randomized, controlled study designed to assess 135 patients across three arms, including two treatment groups and a sham group.
“Completing enrollment of over 135 patients in this U.S.-based Phase 2 study is a critical milestone as we continue our efforts to advance ONL1204 for patients suffering from retinal diseases such as RRD,” said David Esposito, chief executive officer of ONL Therapeutics.
“We are extremely grateful to the patients, families and investigators involved for their dedication and commitment to this study.”

Orion Office REIT Inc. Announces Second Quarter 2023 Results

Retrieved on:

Mercredi, août 9, 2023

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease mission-critical suburban office properties located across the U.S., announced today its operating results for the second quarter ended June 30, 2023.

Key Points:

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease mission-critical suburban office properties located across the U.S., announced today its operating results for the second quarter ended June 30, 2023.
Core FFO for the second quarter of 2023 was $26.9 million, or $0.48 per share, as compared to $28.4 million, or $0.50 per share in the same quarter of 2022.
Due to the timing of an expense reimbursement that fell in the second quarter of 2023, the Company’s results benefited by $0.02 per share in the quarter.
On August 8, 2023, Orion’s Board of Directors declared a quarterly cash dividend of $0.10 per share for the third quarter of 2023, payable on October 16, 2023, to stockholders of record as of September 29, 2023.

Orion Office REIT Inc. Announces Second Quarter 2023 Earnings Release and Webcast Dates

Retrieved on:

Vendredi, juillet 14, 2023

Commercial Building & Real Estate, Construction & Property, REIT, Orion, Webcast, Internet, Acquisition, ONL, NYSE, Cryptocurrency

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease mission-critical suburban office properties located across the U.S., announced today that it will release financial results for the second quarter of 2023 after market close on Wednesday, August 9, 2023.

Key Points:

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease mission-critical suburban office properties located across the U.S., announced today that it will release financial results for the second quarter of 2023 after market close on Wednesday, August 9, 2023.
Orion will host a webcast and conference call to review its financial results at 10:00 a.m.
To participate, the webcast can be accessed live by visiting the “Investors” section of Orion’s website at https://www.onlreit.com/investors .
A replay of the webcast may be accessed via the Internet by visiting the “Investors” section of Orion’s website at https://www.onlreit.com/investors .